All Stories

  1. Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures

    Article • Journal of Crohn s and Colitis, December 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

  2. Vancomycin-resistantEnterococcuscolonise the antibiotic-treated intestine by occupying distinct nutrient- and metabolite-defined intestinal niches

    Article • December 2024, Cold Spring Harbor Laboratory Press

    Dr Benjamin Mullish

  3. Diverse phenotypes, consistent treatment: a study of 30,997 South Asian and White IBD patients using the UK IBD BioResource

    Article • Journal of Crohn s and Colitis, December 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

  4. International consensus statement on microbiome testing in clinical practice

    Article • The Lancet Gastroenterology & Hepatology, December 2024, Elsevier

    Dr Benjamin Mullish

  5. GI highlights from the literature

    Article • Gut, November 2024, BMJ

    Dr Benjamin Mullish

  6. Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

    Article • Gut Microbes, November 2024, Taylor & Francis

    Dr Benjamin Mullish

  7. Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial

    Article • Blood, November 2024, American Society of Hematology

    Dr Benjamin Mullish

  8. New agonists of the incretin/glucagon system for the treatment of metabolic dysfunction-associated steatohepatitis

    Article • Gastroenterology, November 2024, Elsevier

    Dr Benjamin Mullish

  9. Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community

    Article • PLoS ONE, September 2024, PLOS

    Dr Benjamin Mullish

  10. Preface to Special Edition: Microbiome, Inflammation and Cancer

    Article • Best Practice & Research Clinical Gastroenterology, September 2024, Elsevier

    Dr Benjamin Mullish

  11. GI highlights from the literature

    Article • Gut, August 2024, BMJ

    Dr Benjamin Mullish

  12. 3D printed rectal swabs for assessing the gut microbiome, metabolome and inflammation

    Article • Scientific Reports, July 2024, Springer Science + Business Media

    Dr Benjamin Mullish

  13. Inflammation, oxidative stress and gut microbiome perturbation: A narrative review of mechanisms and treatment of the alcohol hangover

    Article • Alcohol Clinical and Experimental Research, July 2024, Wiley

    Dr Benjamin Mullish

  14. Alcohol-Associated liver disease: Emerging therapeutic strategies

    Article • Hepatology, June 2024, Wolters Kluwer Health

    Dr Benjamin Mullish

  15. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

    Article • Hepatology International, June 2024, Springer Science + Business Media

    Dr Benjamin Mullish

  16. FRI-215-YI MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

  17. FRI-286 Muscle function and walking time are associated with better quality of life in MASLD patients

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

  18. OS-070 Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

  19. THU-317 Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

  20. WED-546 Evidence of gut microbiome differences in post-menopausal females with metabolic dysfunction-associated liver disease compared to pre-menopausal females and males

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish

  21. P126 Gut microbiota composition and functionality in a thiopurine-naïve cohort of inflammatory bowel disease (IBD) can differentiate between clinical outcomes

    Article • June 2024, BMJ

    Dr Benjamin Mullish

  22. P61 Ethnic differences in ulcerative colitis: a study of 15,053 South Asian and white patients using the UK IBD bioresource

    Article • June 2024, BMJ

    Dr Benjamin Mullish

  23. Decision

    Article • May 2024, Taylor & Francis

    Dr Benjamin Mullish

  24. The Role of Fecal Microbiota Transplantation in the Treatment of Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease

    Article • May 2024, Taylor & Francis

    Dr Benjamin Mullish

  25. Authors' reply to letter: He who controls Clostridia and Bacteroidia controls the gut microbiome: The concept of targeted probiotics to restore the balance of keystone taxa in irritable bowel syndrome

    Article • Neurogastroenterology & Motility, May 2024, Wiley

    Dr Benjamin Mullish

  26. GI highlights from the literature

    Article • Gut, May 2024, BMJ

    Dr Benjamin Mullish

  27. Mo1870 CONSISTENT APPROACH TO IBD TREATMENT ACROSS SOUTH ASIAN AND WHITE ETHNICITIES IN THE UK DESPITE PHENOTYPIC VARIATIONS: A STUDY OF 33,157 PATIENTS USING THE IBD BIORESOURCE

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

  28. Sa1871 THE COMPOSITION AND FUNCTION OF THE GUT MICROBIOTA IN A TREATMENT NAIVE INCEPTION COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) CAN ACCURATELY DIFFERENTIATE IBD PHENOTYPE.

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

  29. Sa1889 3D PRINTED RECTAL SWABS FOR ASSESSING THE GUT MICROBIOME, METABOLOME, AND INFLAMMATION

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

  30. Sa1927 ANTIBIOTIC TREATMENT PROMOTES THE INTESTINAL COLONISATION OF VANCOMYCIN-RESISTANT ENTEROCOCCUS BY KILLING MEMBERS OF THE GUT MICROBIOTA AND DECREASING NUTRIENT COMPETITION

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

  31. Su1558 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS REDUCE HEPATIC FAT CONTEXT INDEPENDENT OF THE WEIGHT LOSS IN DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

  32. The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond

    Article • Gastroenterology, May 2024, Elsevier

    Dr Benjamin Mullish

  33. The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridioides difficileinfection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society...

    Article • Gut, April 2024, BMJ

    Dr Benjamin Mullish

  34. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS...

    Article • Journal of Hospital Infection, April 2024, Elsevier

    Dr Benjamin Mullish

  35. Lyophilized fecal microbiome transfer for primary Clostridioides difficile infection: a multicenter randomized controlled trial (DONATE Study)

    Article • Open Research Europe, March 2024, Faculty of 1000, Ltd.

    Dr Benjamin Mullish

  36. Overview of the second edition of the joint British Society of Gastroenterology and Healthcare Infection Society faecal microbiota transplant guidelines, 2024

    Article • Journal of Hospital Infection, March 2024, Elsevier

    Dr Benjamin Mullish

  37. The beneficial hepatic effects of glucagon‐like peptide 1 receptor agonists in patients with diabetes and metabolic dysfunction‐associated steatotic liver disease are independent of weight loss

    Article • Liver International Communications, March 2024, Wiley

    Dr Benjamin Mullish

  38. GI highlights from the literature

    Article • Gut, February 2024, BMJ

    Dr Benjamin Mullish

  39. A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females

    Article • Neurogastroenterology & Motility, January 2024, Wiley

    Dr Benjamin Mullish

  40. Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

    Article • Gut Microbes, January 2024, Taylor & Francis

    Dr Benjamin Mullish

  41. Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial

    Article • RMD Open, January 2024, BMJ

    Dr Benjamin Mullish

  42. OP07 Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResource

    Article • Journal of Crohn s and Colitis, January 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

  43. P1209 Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis

    Article • Journal of Crohn s and Colitis, January 2024, Oxford University Press (OUP)

    Dr Benjamin Mullish

  44. Risk Factors for Liver Cancer and Chronic Liver Disease-related Death: Are Sugar Substitutes Better Than the Real Thing?

    Article • Gastroenterology, January 2024, Elsevier

    Dr Benjamin Mullish

  45. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients

    Article • Journal of Hepatology, January 2024, Elsevier

    Dr Benjamin Mullish

  46. Liver sinusoidal cells in the diagnosis and treatment of liver diseases: Role of hepatic stellate cells

    Article • January 2024, Elsevier

    Dr Benjamin Mullish

  47. Evaluating Protocols for Reproducible Targeted Metabolomics by NMR

    Article • The Analyst, January 2024, Royal Society of Chemistry

    Dr Benjamin Mullish

  48. Pharmacotherapy in Managing Alcohol-Use Disorder

    Article • Gastroenterology, December 2023, Elsevier

    Dr Benjamin Mullish

  49. The role of faecal microbiota transplantation in chronic noncommunicable disorders

    Article • Journal of Autoimmunity, December 2023, Elsevier

    Dr Benjamin Mullish

  50. GI highlights from the literature

    Article • Gut, November 2023, BMJ

    Dr Benjamin Mullish

  51. Gut microbiota and immunotherapy of renal cell carcinoma

    Article • Human Vaccines & Immunotherapeutics, November 2023, Taylor & Francis

    Dr Benjamin Mullish

  52. Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

    Article • Nature Medicine, November 2023, Springer Science + Business Media

    Dr Benjamin Mullish

  53. THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD

    Article • Journal of the Endocrine Society, October 2023, Endocrine Society

    Dr Benjamin Mullish

  54. Alcohol Minimum Unit Pricing Reduces Alcohol-Specific Hospitalizations and Deaths

    Article • Gastroenterology, October 2023, Elsevier

    Dr Benjamin Mullish

  55. Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA<...

    Article • ACR Open Rheumatology, September 2023, Wiley

    Dr Benjamin Mullish

  56. A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies

    Article • Liver International, September 2023, Wiley

    Dr Benjamin Mullish

  57. O6 The beneficial hepatic-effect of glucagon-like peptide 1 receptor agonists in diabetic patients with non-alcoholic fatty liver disease

    Article • September 2023, BMJ

    Dr Benjamin Mullish

  58. P18 A 5 sit-to-stand test may identify NAFLD patients at higher risk for worse clinical outcomes

    Article • September 2023, BMJ

    Dr Benjamin Mullish

  59. P26 Exploring the association between quality of life, diet, physical activity, and binge eating disorder in NAFLD patients in a tertiary centre of care

    Article • September 2023, BMJ

    Dr Benjamin Mullish

  60. Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites

    Article • Nature Communications, August 2023, Springer Science + Business Media

    Dr Benjamin Mullish

  61. GI highlights from the literature

    Article • Gut, August 2023, BMJ

    Dr Benjamin Mullish

  62. Faecal microbiota transplant restores intestinal barrier function and augments ammonia metabolism in patients with cirrhosis: a randomised single-blind placebo-controlled trial

    Article • July 2023, Research Square

    Dr Benjamin Mullish

  63. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

    Article • Nature Medicine, July 2023, Springer Science + Business Media

    Dr Benjamin Mullish

  64. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

    Article • Nature Medicine, July 2023, Springer Science + Business Media

    Dr Benjamin Mullish

  65. Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease

    Article • Journal of Hepatology, June 2023, Elsevier

    Dr Benjamin Mullish

  66. P79 COVID-19 vaccine-induced antibody response is associated with oral microbiota composition in patients with inflammatory bowel disease, cirrhosis, and liver transplantation

    Article • June 2023, BMJ

    Dr Benjamin Mullish

  67. P325 Colonoscopy surveillance in primary sclerosing cholangitis patients during the COVID-19 pandemic – a tertiary centre experience

    Article • June 2023, BMJ

    Dr Benjamin Mullish

  68. Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomised single-blind placebo-controlled trial

    Article • Journal of Hepatology, June 2023, Elsevier

    Dr Benjamin Mullish

  69. Investigating the correlation of a poly-metabolic risk score to clinical features in non-alcoholic fatty liver disease patients throughout a faecal microbiota transplant clinical trial

    Article • Journal of Hepatology, June 2023, Elsevier

    Dr Benjamin Mullish

  70. Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease

    Article • Journal of Hepatology, June 2023, Elsevier

    Dr Benjamin Mullish

  71. Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients

    Article • Journal of Hepatology, June 2023, Elsevier

    Dr Benjamin Mullish

  72. Short-chain fatty and carboxylic acid changes associated with fecal microbiota transplant communally influence microglial inflammation

    Article • Heliyon, June 2023, Elsevier

    Dr Benjamin Mullish

  73. The Impact of Proportional Dietary Carbohydrate and Fat Content on Type 2 Diabetes and NAFLD

    Article • Gastroenterology, June 2023, Elsevier

    Dr Benjamin Mullish

  74. POS0423 PLASMA METABOLOMIC PROFILES OF PATIENTS WITH ACTIVE PERIPHERAL PSORIATIC ARTHRITIS CAN DIFFERENTIATE TREATMENT RESPONDERS FROM FAILURES: EXPLORATORY FINDINGS FROM THE FLORA TRIAL

    Article • May 2023, BMJ

    Dr Benjamin Mullish

  75. A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease

    Article • Movement Disorders, May 2023, Wiley

    Dr Benjamin Mullish

  76. Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy

    Article • Antibiotics, May 2023, MDPI AG

    Dr Benjamin Mullish

  77. GI highlights from the literature

    Article • Gut, May 2023, BMJ

    Dr Benjamin Mullish

  78. Increased risk of cirrhosis in post-menopausal women with NAFLD

    Article • Endocrine Abstracts, May 2023, Bioscientifica

    Dr Benjamin Mullish

  79. Tu1866 SALIVARY MICROBIOTA COMPOSITION IS ASSOCIATED WITH ANTIBODY RESPONSE FOLLOWING COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE, CIRRHOSIS AND LIVER TRANSPLANTATION

    Article • Gastroenterology, May 2023, Elsevier

    Dr Benjamin Mullish

  80. Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective

    Article • Nutrients, April 2023, MDPI AG

    Dr Benjamin Mullish

  81. Screening for NAFLD—Current Knowledge and Challenges

    Article • Metabolites, April 2023, MDPI AG

    Dr Benjamin Mullish

  82. The gastrointestinal status of healthy adults: a post hoc assessment of the impact of three distinct probiotics

    Article • Beneficial Microbes, April 2023, Wageningen Academic Publishers

    Dr Benjamin Mullish

  83. GI highlights from the literature

    Article • Gut, April 2023, BMJ

    Dr Benjamin Mullish

  84. Antibiotics promote intestinal growth of carbapenem-resistantEnterobacteriaceaeby enriching nutrients and depleting microbial metabolites

    Article • March 2023, Cold Spring Harbor Laboratory Press

    Dr Benjamin Mullish

  85. Prospective evaluation of screening strategies for NAFLD in people with type-2 diabetes mellitus in the community

    Article • Digestive and Liver Disease, March 2023, Elsevier

    Dr Benjamin Mullish

  86. Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease

    Article • International Journal of Molecular Sciences, February 2023, MDPI AG

    Dr Benjamin Mullish

  87. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients

    Article • EBioMedicine, February 2023, Elsevier

    Dr Benjamin Mullish

  88. Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition

    Article • Scientific Reports, January 2023, Springer Science + Business Media

    Dr Benjamin Mullish

  89. GI highlights from the literature

    Article • Gut, January 2023, BMJ

    Dr Benjamin Mullish

  90. Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome

    Article • Clinical and Translational Medicine, January 2023, Wiley

    Dr Benjamin Mullish

  91. Editorial: the acid test—can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply

    Article • Alimentary Pharmacology & Therapeutics, December 2022, Wiley

    Dr Benjamin Mullish

  92. Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans

    Article • Nutrients, December 2022, MDPI AG

    Dr Benjamin Mullish

  93. GI highlights from the literature

    Article • Gut, November 2022, BMJ

    Dr Benjamin Mullish

  94. 627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy

    Article • November 2022, BMJ

    Dr Benjamin Mullish

  95. 614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

    Article • November 2022, BMJ

    Dr Benjamin Mullish

  96. Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel

    Article • The Lancet Gastroenterology & Hepatology, November 2022, Elsevier

    Dr Benjamin Mullish

  97. Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection

    Article • Alimentary Pharmacology & Therapeutics, October 2022, Wiley

    Dr Benjamin Mullish

  98. Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

    Article • October 2022, Research Square

    Dr Benjamin Mullish

  99. UEG Week 2022 Poster Presentations

    Article • United European Gastroenterology Journal, October 2022, Wiley

    Dr Benjamin Mullish

  100. Polymorphic microbes: a new emerging hallmark of cancer

    Article • Trends in Microbiology, September 2022, Elsevier

    Dr Benjamin Mullish

  101. New insights into host‐microbiome crosstalk in psoriatic skin

    Article • Clinical and Translational Discovery, September 2022, Wiley

    Dr Benjamin Mullish

  102. Recent Findings in the Gut-Liver Axis and Associated Disease Therapy

    Article • EMJ Hepatology, August 2022, European Medical Group

    Dr Benjamin Mullish

  103. GI highlights from the literature

    Article • Gut, August 2022, BMJ

    Dr Benjamin Mullish

  104. Further Insights Into the Impact of Bariatric Surgery on the Progression of Nonalcoholic Fatty Liver Disease

    Article • Gastroenterology, August 2022, Elsevier

    Dr Benjamin Mullish

  105. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

    Article • International Journal of Molecular Sciences, July 2022, MDPI AG

    Dr Benjamin Mullish

  106. A study evaluating outcomes of a virtual specialist liver cirrhosis clinic

    Article • Journal of Hepatology, July 2022, Elsevier

    Dr Benjamin Mullish

  107. Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus

    Article • Journal of Hepatology, July 2022, Elsevier

    Dr Benjamin Mullish

  108. Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls

    Article • Journal of Hepatology, July 2022, Elsevier

    Dr Benjamin Mullish

  109. Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD

    Article • Journal of Hepatology, July 2022, Elsevier

    Dr Benjamin Mullish

  110. Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study

    Article • Journal of Hepatology, July 2022, Elsevier

    Dr Benjamin Mullish

  111. Intestinal microbiota transplantation: do not forget the metabolites

    Article • The Lancet Gastroenterology & Hepatology, July 2022, Elsevier

    Dr Benjamin Mullish

  112. Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases

    Article • Journal of Hepatology, July 2022, Elsevier

    Dr Benjamin Mullish

  113. Fecal bile acid profiles predict recurrence in patients with primary Clostridioides difficile infection

    Article • June 2022, Cold Spring Harbor Laboratory Press

    Dr Benjamin Mullish

  114. GI highlights from the literature

    Article • Gut, June 2022, BMJ

    Dr Benjamin Mullish

  115. P2 COVID-19 vaccination response in immunosuppressed patients with IBD is associated with altered gut microbiota function

    Article • June 2022, BMJ

    Dr Benjamin Mullish

  116. The gut microbiota and metabolome is associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients

    Article • May 2022, Research Square

    Dr Benjamin Mullish

  117. Identifying transient and stable bacteria- metabolite interactions from longitudinal multi-omics data

    Article • May 2022, Research Square

    Dr Benjamin Mullish

  118. Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome

    Article • BMC Gastroenterology, May 2022, Springer Science + Business Media

    Dr Benjamin Mullish

  119. 643: CLINICAL AND ECONOMICAL EVALUATION OF COMMUNITY-BASED PREVENTATIVE SCREENING STRATEGIES FOR NON-ALCOHOLIC FATTY LIVER DISEASE

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  120. 681: FACTORS ASSOCIATED WITH INCREASED GUT PERMEABILITY AND SEVERITY OF LIVER DISEASE IN DIABETIC PATIENTS WITH NAFLD

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  121. 894: RELATIVE CHANGE OF ENTEROCOCCUS FAECIUM, SELECTED COMMENSAL BACTERIA AND CYTOKINES ARE SEEN IN PATIENTS COLONIZED WITH MULTIDRUG-RESISTANT ORGANISMS WHO UNDERGO INTESTINAL MICROBIOTA TRANSPLANTATION.

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  122. Mo1589: IMPACT ON GUT MICROBIAL METABOLITES FROM A 6-MONTH DOUBLEBLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF FECAL MICROBIOTA TRANSPLANTATION FOR ACTIVE PERIPHERAL PSORIATIC ARTHRITIS

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  123. Sa1657: NEW LINKS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOME SUGGEST A STRONGER ROLE OF THE GUT-JOINT AXIS

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  124. Su1601: INTESTINAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIODIOIDES DIFFICILE INFECTION IS ASSOCIATED WITH RESTORATION OF MICROBIAL ARYLSULFATASES AND SULFATIDE DEGRADATION

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  125. Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  126. Tu1312: EXAMINING THE CORRELATION OF HISTOLOGICAL FEATURES OF NAFLD WITH A POLYMETABOLIC RISK SCORE FOR PREDICTING PATIENTS WITH NAFLD

    Article • Gastroenterology, May 2022, Elsevier

    Dr Benjamin Mullish

  127. Impact of gastrointestinal surgery upon the gut microbiome: A systematic review

    Article • Surgery, May 2022, Elsevier

    Dr Benjamin Mullish

  128. How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection

    Article • Clinical Microbiology and Infection, April 2022, Elsevier

    Dr Benjamin Mullish

  129. GI highlights from the literature

    Article • Gut, March 2022, BMJ

    Dr Benjamin Mullish

  130. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases

    Article • Gut Microbes, March 2022, Taylor & Francis

    Dr Benjamin Mullish

  131. Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition

    Article • March 2022, Research Square

    Dr Benjamin Mullish

  132. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease

    Article • International Journal of Molecular Sciences, January 2022, MDPI AG

    Dr Benjamin Mullish

  133. The potential of fecal microbiota transplantation in oncology

    Article • Trends in Microbiology, January 2022, Elsevier

    Dr Benjamin Mullish

  134. Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?

    Article • World Journal of Hepatology, December 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Benjamin Mullish

  135. GI highlights from the literature

    Article • Gut, December 2021, BMJ

    Dr Benjamin Mullish

  136. A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection

    Article • Cells, November 2021, MDPI AG

    Dr Payton Tung On Yau, Dr Benjamin Mullish

  137. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease

    Article • Alimentary Pharmacology & Therapeutics, November 2021, Wiley

    Dr Benjamin Mullish

  138. Clostridioides difficile: innovations in target discovery and potential for therapeutic success

    Article • Expert Opinion on Therapeutic Targets, November 2021, Taylor & Francis

    Dr Benjamin Mullish

  139. Outcomes of postmenopausal women with non-alcoholic fatty liver disease (NAFLD)

    Article • Endocrine Abstracts, October 2021, Bioscientifica

    Dr Benjamin Mullish

  140. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series

    Article • American Journal of Hematology, October 2021, Wiley

    Dr Benjamin Mullish

  141. GI highlights from the literature

    Article • Gut, October 2021, BMJ

    Dr Benjamin Mullish

  142. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey

    Article • The Lancet Regional Health - Europe, October 2021, Elsevier

    Dr Benjamin Mullish

  143. Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use

    Article • European Medical Journal, September 2021, European Medical Group

    Dr Benjamin Mullish

  144. Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation

    Article • Frontiers in Cellular and Infection Microbiology, August 2021, Frontiers

    Dr Benjamin Mullish

  145. GI highlights from the literature

    Article • Gut, August 2021, BMJ

    Dr Benjamin Mullish

  146. Binge‐eating disorder is associated with an unfavorable body mass composition in patients with non‐alcoholic fatty liver disease

    Article • International Journal of Eating Disorders, July 2021, Wiley

    Dr Benjamin Mullish

  147. Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India

    Article • Microorganisms, July 2021, MDPI AG

    Dr Payton Tung On Yau, Dr Benjamin Mullish

  148. Rapid resolution of COVID-19 after faecal microbiota transplantation

    Article • Gut, July 2021, BMJ

    Dr Benjamin Mullish

  149. GI highlights from the literature

    Article • Gut, May 2021, BMJ

    Dr Benjamin Mullish

  150. 739 DAILY PROBIOTIC USE IS ASSOCIATED WITH A REDUCED RATE OF UPPER RESPIRATORY TRACT SYMPTOMS IN OVERWEIGHT AND OBESE PEOPLE

    Article • Gastroenterology, May 2021, Elsevier

    Dr Benjamin Mullish

  151. 811 FECAL MICROBIOTA TRANSPLANT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN PATIENTS COLONIZED WITH MULTI-DRUG RESISTANT ORGANISMS IS ASSOCIATED WITH IMPROVED SURVIVAL

    Article • Gastroenterology, May 2021, Elsevier

    Dr Benjamin Mullish

  152. Fr571 A DISTINCTIVE SIGNATURE OF FECAL BILE ACIDS AND OTHER NOVEL METABOLITES ACCOMPANYING RECURRENCE AFTER PRIMARY CLOSTRIDIOIDES DIFFICILE INFECTION

    Article • Gastroenterology, May 2021, Elsevier

    Dr Benjamin Mullish

  153. Fr573 ASSOCIATION BETWEEN NOVEL METABOLOMIC BIOMARKERS AND C.DIFFICILE RECURRENCE

    Article • Gastroenterology, May 2021, Elsevier

    Dr Benjamin Mullish

  154. Sa022 A HIGH-FIBER LOW-FAT DIET INCREASES FECAL LEVELS OF LITHOCHOLIC ACID DERIVATIVE 3-KETOCHOLANIC ACID

    Article • Gastroenterology, May 2021, Elsevier

    Dr Benjamin Mullish

  155. Su541 RECTAL SWABS AS A VIABLE ALTERNATIVE TO FECAL SAMPLING FOR THE ANALYSIS OF GUT MICROBIOME FUNCTIONALITY AS WELL AS COMPOSITION

    Article • Gastroenterology, May 2021, Elsevier

    Dr Benjamin Mullish

  156. SARS-CoV-2 vaccines and donor recruitment for FMT

    Article • The Lancet Gastroenterology & Hepatology, April 2021, Elsevier

    Dr Benjamin Mullish

  157. Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice

    Article • Journal of Gastrointestinal and Liver Diseases, March 2021, Romanian Society of Gastroenterology and Heptatology

    Dr Benjamin Mullish

  158. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections

    Article • Frontline Gastroenterology, March 2021, BMJ

    Dr Benjamin Mullish

  159. GI highlights from the literature

    Article • Gut, March 2021, BMJ

    Dr Benjamin Mullish

  160. Fecal Microbiota Transplantation: The Evolving Risk Landscape

    Article • The American Journal of Gastroenterology, February 2021, Wolters Kluwer Health

    Dr Benjamin Mullish

  161. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity

    Article • HORMONES, January 2021, Springer Science + Business Media

    Dr Benjamin Mullish

  162. Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults

    Article • Scientific Reports, January 2021, Springer Science + Business Media

    Dr Benjamin Mullish

  163. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?

    Article • Gut Microbes, January 2021, Taylor & Francis

    Dr Benjamin Mullish

  164. NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials

    Article • Journal of Hepatology, January 2021, Elsevier

    Dr Benjamin Mullish

  165. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection

    Article • Therapeutic Advances in Gastroenterology, January 2021, SAGE Publications

    Dr Benjamin Mullish

  166. Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Dr Benjamin Mullish

  167. P307 FMT-associated alterations in the TCR repertoire of patients with severe or fulminant clostridioides difficile infection

    Article • January 2021, BMJ

    Dr Benjamin Mullish

  168. Non-Alcoholic Fatty Liver Disease and Vascular Disease

    Article • Current Vascular Pharmacology, December 2020, Bentham Science Publishers

    Dr Benjamin Mullish

  169. Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection

    Article • Gut Microbes, December 2020, Taylor & Francis

    Prof. Marcin Frankowski, Dr Benjamin Mullish

  170. The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (O010-O173)

    Article • British Journal of Pharmacology, December 2020, Springer Science + Business Media

    Dr Benjamin Mullish

  171. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis

    Article • EClinicalMedicine, December 2020, Elsevier

    Dr Benjamin Mullish

  172. GI highlights from the literature

    Article • Gut, November 2020, BMJ

    Dr Benjamin Mullish

  173. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection

    Article • Inflammatory Bowel Diseases, November 2020, Oxford University Press (OUP)

    Dr Benjamin Mullish

  174. Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection

    Article • Gastroenterology, November 2020, Elsevier

    Dr Benjamin Mullish

  175. A Guide to the Gut Microbiome and its Relevance to Critical Care

    Article • British Journal of Nursing, October 2020, Mark Allen Group

    Dr Benjamin Mullish

  176. Letter: intestinal microbiota transfer—updating the nomenclature to increase acceptability

    Article • Alimentary Pharmacology & Therapeutics, October 2020, Wiley

    Dr Benjamin Mullish

  177. Reply to Woodworth, et al.

    Article • Clinical Infectious Diseases, October 2020, Oxford University Press (OUP)

    Dr Benjamin Mullish

  178. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19

    Article • PLoS ONE, October 2020, PLOS

    Dr Benjamin Mullish

  179. Abstract Supplement ACR Convergence 2020

    Article • Arthritis & Rheumatology, October 2020, Wiley

    Dr Benjamin Mullish

  180. S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection

    Article • The American Journal of Gastroenterology, October 2020, Wolters Kluwer Health

    Dr Benjamin Mullish

  181. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites

    Article • Gut Microbes, September 2020, Taylor & Francis

    Dr Benjamin Mullish

  182. Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?

    Article • Clinical Immunology, September 2020, Elsevier

    Dr Benjamin Mullish

  183. Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders

    Article • Future Microbiology, August 2020, Future Medicine

    Dr Benjamin Mullish

  184. High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease

    Article • Clinical Gastroenterology and Hepatology, August 2020, Elsevier

    Dr Benjamin Mullish

  185. Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis

    Article • Journal of Hepatology, August 2020, Elsevier

    Dr Benjamin Mullish

  186. Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms

    Article • Clinical Infectious Diseases, July 2020, Oxford University Press (OUP)

    Dr Benjamin Mullish

  187. Letter: faecal microbiota transplantation for IBS

    Article • Alimentary Pharmacology & Therapeutics, July 2020, Wiley

    Dr Benjamin Mullish

  188. Letter: liver disease and COVID‐19—not the perfect storm

    Article • Alimentary Pharmacology & Therapeutics, July 2020, Wiley

    Dr Benjamin Mullish

  189. GI highlights from the literature

    Article • Gut, July 2020, BMJ

    Dr Benjamin Mullish

  190. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

    Article • Gut, July 2020, BMJ

    Dr Benjamin Mullish

  191. Correction to Lancet Gastroenterol Hepatol 2020; 5: 430–31

    Article • The Lancet Gastroenterology & Hepatology, June 2020, Elsevier

    Dr Benjamin Mullish

  192. 1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION

    Article • Gastroenterology, May 2020, Elsevier

    Dr Benjamin Mullish

  193. 121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION

    Article • Gastroenterology, May 2020, Elsevier

    Dr Benjamin Mullish

  194. 644 IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED METABOLITES AFTER FECAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION

    Article • Gastroenterology, May 2020, Elsevier

    Dr Benjamin Mullish

  195. Mo1939 TEMPORAL MODULATION OF TCR REPERTOIRE FOLLOWING SEQUENTIAL FMT TREATMENT IN PATIENTS WITH SEVERE OR FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION

    Article • Gastroenterology, May 2020, Elsevier

    Dr Benjamin Mullish

  196. Sa1923 IDENTIFICATION OF NEW ASSOCIATIONS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOTA, A PHENOMIC STUDY

    Article • Gastroenterology, May 2020, Elsevier

    Dr Benjamin Mullish

  197. Tu1909 IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON PREVENTION OF METABOLIC SYNDROME AMONG PATIENTS WITH OBESITY

    Article • Gastroenterology, May 2020, Elsevier

    Dr Benjamin Mullish

  198. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel

    Article • The Lancet Gastroenterology & Hepatology, May 2020, Elsevier

    Dr Benjamin Mullish

  199. Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?

    Article • Gut, April 2020, BMJ

    Dr Benjamin Mullish

  200. GI highlights from the literature

    Article • Gut, April 2020, BMJ

    Dr Benjamin Mullish

  201. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients

    Article • Clinical Gastroenterology and Hepatology, April 2020, Elsevier

    Dr Benjamin Mullish

  202. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

    Article • Scientific Reports, March 2020, Springer Science + Business Media

    Dr Benjamin Mullish

  203. GI highlights from the literature

    Article • Gut, March 2020, BMJ

    Dr Benjamin Mullish

  204. Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy

    Article • Scientific Reports, March 2020, Springer Science + Business Media

    Dr Benjamin Mullish

  205. The gut microbiome: what every gastroenterologist needs to know

    Article • Frontline Gastroenterology, February 2020, BMJ

    Dr Benjamin Mullish

  206. Case-control study of recurrent Extended-Spectrum Beta Lactamase Enterobacteriaceae Urinary Tract Infections (ESBL UTIs): the management challenges

    Article • Access Microbiology, February 2020, Society for General Microbiology

    Dr Benjamin Mullish

  207. Cohort study of Faecal Microbiota Transplantation for patient’s colonised with MDROs - successful prevention of invasive disease despite low decolonisation rates

    Article • Access Microbiology, February 2020, Society for General Microbiology

    Dr Benjamin Mullish

  208. Faecal microbiota transplantations and urinary tract infections – Authors' reply

    Article • The Lancet, January 2020, Elsevier

    Dr Benjamin Mullish

  209. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease

    Article • Therapeutic Advances in Gastroenterology, January 2020, SAGE Publications

    Dr Benjamin Mullish

  210. P844 Higher proportions of genera and species in the Firmicutes phylum are associated with a healthy pouch compared with patients with chronic pouchitis

    Article • Journal of Crohn s and Colitis, January 2020, Oxford University Press (OUP)

    Dr Benjamin Mullish

  211. The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?

    Article • Therapeutic Advances in Gastroenterology, January 2020, SAGE Publications

    Dr Benjamin Mullish

  212. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

    Article • Immunology, November 2019, Wiley

    Dr Benjamin Mullish

  213. Antibiotic therapy and outcome from immune-checkpoint inhibitors

    Article • Journal for ImmunoTherapy of Cancer, November 2019, BMJ

    Dr Benjamin Mullish

  214. Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non‐alcoholic fatty liver disease—authors' reply

    Article • Alimentary Pharmacology & Therapeutics, October 2019, Wiley

    Dr Benjamin Mullish

  215. 185 Evaluating Dynamics of Bile Acid Metabolism to Predict Recurrence of Clostridioides difficile Infection

    Article • The American Journal of Gastroenterology, October 2019, Wolters Kluwer Health

    Dr Benjamin Mullish

  216. 837 Short Chain Fatty Acid Profiles Are Altered by Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection

    Article • The American Journal of Gastroenterology, October 2019, Wolters Kluwer Health

    Dr Benjamin Mullish

  217. Posters (Abstracts 289–2348)

    Article • Hepatology, October 2019, Wolters Kluwer Health

    Dr Benjamin Mullish

  218. Guidelines - Stool banking for faecal microbiota transplantation in clinical practice

    Article • Gut, September 2019, BMJ

    Giovanni Cammarota, Dr Benjamin Mullish

  219. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

    Article • The Lancet, August 2019, Elsevier

    Dr Benjamin Mullish

  220. Faecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: ‘A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enter...

    Article • Clinical Microbiology and Infection, July 2019, Elsevier

    Dr Benjamin Mullish

  221. BAUS 2019 Abstract Book

    Article • Journal of Clinical Urology, June 2019, SAGE Publications

    Dr Benjamin Mullish

  222. Recurrent bacteraemia following variceal haemorrhage

    Article • Gut, June 2019, BMJ

    Dr Benjamin Mullish

  223. In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation

    Article • Gut Microbes, May 2019, Taylor & Francis

    Dr Tanya M Monaghan, Dr Benjamin Mullish

  224. 621 – Fecal Microbiota Transplantation for the Treatment of Obesity: A Randomized, Placebo-Controlled Pilot Trial

    Article • Gastroenterology, May 2019, Elsevier

    Dr Benjamin Mullish

  225. 7 – The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation

    Article • Gastroenterology, May 2019, Elsevier

    Dr Benjamin Mullish

  226. Mo1953 – Growth Inhibition of Clostridioides Difficile by Short and Medium Chain Fatty Acids

    Article • Gastroenterology, May 2019, Elsevier

    Dr Benjamin Mullish

  227. Sa1924 – Effect of Short Chain Fatty Acids on Gut-Brain Axis Using a Microglial Cell Model

    Article • Gastroenterology, May 2019, Elsevier

    Dr Benjamin Mullish

  228. MP71-15 PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY

    Article • The Journal of Urology, April 2019, Wolters Kluwer Health

    Dr Benjamin Mullish

  229. PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Benjamin Mullish

  230. SAT-294-Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Benjamin Mullish

  231. THU-306-Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Benjamin Mullish

  232. THU-331-Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Benjamin Mullish

  233. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non‐alcoholic fatty liver disease – authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, March 2019, Wiley

    Dr Benjamin Mullish

  234. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume

    Article • Alimentary Pharmacology & Therapeutics, March 2019, Wiley

    Dr Benjamin Mullish

  235. Prevalence of recurrent extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTIs) in patients within a urology service. Introducing the concept of faecal Microbiota transplantation (FMT) as a treatment modality

    Article • European Urology Supplements, March 2019, Elsevier

    Dr Benjamin Mullish

  236. Current and future targets for faecal microbiota transplantation

    Article • Human Microbiome Journal, March 2019, Elsevier

    Dr Benjamin Mullish

  237. Current and future pharmacological therapies for managing cirrhosis and its complications

    Article • World Journal of Gastroenterology, February 2019, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Benjamin Mullish

  238. Liver Biopsy

    Article • February 2019, Wiley

    Dr Benjamin Mullish

  239. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection

    Article • Gut, February 2019, BMJ

    Dr Benjamin Mullish

  240. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial

    Article • The American Journal of Gastroenterology, January 2019, Wolters Kluwer Health

    Dr Benjamin Mullish

  241. The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease

    Article • Therapeutic Advances in Gastroenterology, January 2019, SAGE Publications

    Dr Benjamin Mullish

  242. Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease

    Article • Therapeutic Advances in Gastroenterology, January 2019, SAGE Publications

    Dr Benjamin Mullish

  243. 1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing Enterobacteriaceae

    Article • Open Forum Infectious Diseases, November 2018, Oxford University Press (OUP)

    Dr Benjamin Mullish

  244. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota

    Article • Gastroenterology, November 2018, Elsevier

    Dr Benjamin Mullish

  245. Non-alcoholic fatty liver disease and cardiovascular risk: an update

    Article • Expert Review of Gastroenterology & Hepatology, October 2018, Taylor & Francis

    Dr Benjamin Mullish

  246. Bile Acid Profiles are Not Altered by Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis: Category Award (Liver): Presidential Poster Award

    Article • The American Journal of Gastroenterology, October 2018, Wolters Kluwer Health

    Dr Benjamin Mullish

  247. Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines

    Article • Journal of Hospital Infection, October 2018, Elsevier

    Dr Benjamin Mullish

  248. Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease

    Article • Methods, October 2018, Elsevier

    Dr Benjamin Mullish

  249. Posters (Abstracts 301–2389)

    Article • Hepatology, October 2018, Wolters Kluwer Health

    Dr Benjamin Mullish

  250. Publisher’s Note: Poster Abstract

    Article • Open Forum Infectious Diseases, October 2018, Oxford University Press (OUP)

    Dr Benjamin Mullish

  251. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway

    Article • Gut Microbes, September 2018, Taylor & Francis

    Dr Tanya M Monaghan, Dr Benjamin Mullish

  252. The implementation of omics technologies in cancer microbiome research

    Article • ecancermedicalscience, September 2018, Cancer Intelligence

    Dr Benjamin Mullish

  253. Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study

    Article • Scandinavian Journal of Gastroenterology, September 2018, Taylor & Francis

    lawrence penez, Dr Benjamin Mullish

  254. Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant

    Article • Hepatology, September 2018, Wolters Kluwer Health

    Dr Benjamin Mullish

  255. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

    Article • Journal of Hospital Infection, September 2018, Elsevier

    Dr Benjamin Mullish

  256. The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

    Article • Gut, August 2018, BMJ

    Dr Benjamin Mullish

  257. 0503 - A novel route for controlling Clostridioides difficile growth via bile acid and short chain fatty acid modulation

    Article • August 2018, Morressier

    Dr Benjamin Mullish

  258. Clostridium difficile infection and antibiotic-associated diarrhoea

    Article • Clinical Medicine, June 2018, Elsevier

    Dr Benjamin Mullish

  259. IDDF2018-ABS-0056 Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study

    Article • June 2018, BMJ

    Dr Benjamin Mullish

  260. PWE-052 Long term outcomes of initial IFX therapy for inflammatory pouch pathology: a multi-centre retrospective study

    Article • June 2018, BMJ

    Dr Benjamin Mullish

  261. Letter: improvements in mental health after faecal microbiota transplantation—an underexplored treatment‐related benefit?

    Article • Alimentary Pharmacology & Therapeutics, May 2018, Wiley

    Dr Benjamin Mullish

  262. 24 - A Novel Route to Controlling Clostridioides Difficile Growth via Short Chain Fatty Acid and Bile Acid Modulation

    Article • Gastroenterology, May 2018, Elsevier

    Dr Benjamin Mullish

  263. 25 - Microbiome and Metabolic Markers of Clostridium Difficile Recurrance

    Article • Gastroenterology, May 2018, Elsevier

    Dr Benjamin Mullish

  264. Tu1894 - Potential Motivators and Deterents for Stool Donors: A Multicenter Study

    Article • Gastroenterology, May 2018, Elsevier

    Dr Benjamin Mullish

  265. A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease

    Article • Journal of Hepatology, April 2018, Elsevier

    Dr Benjamin Mullish

  266. Gastrointestinal: Duodenal variceal bleeding secondary to thrombophilia‐related portal vein thrombosis

    Article • Journal of Gastroenterology and Hepatology, January 2018, Wiley

    Dr Benjamin Mullish

  267. P141 Infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study

    Article • Journal of Crohn s and Colitis, January 2018, Oxford University Press (OUP)

    Dr Benjamin Mullish

  268. Posters (Abstracts 264-2239)

    Article • Hepatology, October 2017, Wiley

    Raghubendra Dagur, Dr Benjamin Mullish

  269. Comparative epidemiology of Clostridium difficile infection: England and the USA

    Article • International Journal for Quality in Health Care, September 2017, Oxford University Press (OUP)

    Dr Benjamin Mullish

  270. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial

    Article • Hepatology, August 2017, Wolters Kluwer Health

    Dr Benjamin Mullish

  271. Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality

    Article • British Journal of Pharmacology, July 2017, Springer Science + Business Media

    Dr Benjamin Mullish

  272. PWE-093 Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine: histological images in patients with non-alcoholic fatty liver disease

    Article • June 2017, BMJ

    Dr Benjamin Mullish

  273. PWE-094 The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease

    Article • June 2017, BMJ

    Dr Benjamin Mullish

  274. Anticoagulation in chronic liver disease

    Article • Journal of Hepatology, June 2017, Elsevier

    Dr Benjamin Mullish

  275. Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes

    Article • Gastroenterology, April 2017, Elsevier

    Dr Benjamin Mullish

  276. National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK

    Article • Journal of Hospital Infection, April 2017, Elsevier

    Dr Benjamin Mullish

  277. The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease

    Article • Journal of Hepatology, January 2017, Elsevier

    Dr Benjamin Mullish

  278. Meeting update: faecal microbiota transplantation––bench, bedside, courtroom?

    Article • Frontline Gastroenterology, November 2016, BMJ

    Dr Benjamin Mullish

  279. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance

    Article • BMJ, September 2016, BMJ

    Dr Benjamin Mullish

  280. OC-040 National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom

    Article • Gut, June 2016, BMJ

    Dr Benjamin Mullish

  281. PWE-094 Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?

    Article • Gut, June 2016, BMJ

    Dr Benjamin Mullish

  282. Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces

    Article • Analytical Chemistry, April 2016, American Chemical Society (ACS)

    Dr Benjamin Mullish

  283. Cardiology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  284. Clinical haematology and oncology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  285. Clinical sciences

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  286. Dermatology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  287. Endocrinology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  288. Gastroenterology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  289. Geriatric medicine

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  290. Infectious diseases and GUM

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  291. Nephrology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  292. Neurology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  293. Ophthalmology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  294. Psychiatry

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  295. Respiratory medicine

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  296. Rheumatology

    Article • January 2016, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  297. Obstacles to establishing an NHS faecal transplant programme

    Article • BMJ, November 2015, BMJ

    Dr Benjamin Mullish

  298. Letter: depression and the use of anti-depressants in patients with chronic liver disease or liver transplantation - authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, April 2015, Wiley

    Dr Benjamin Mullish

  299. Weight loss in a man from West Africa

    Article • Gut, March 2015, BMJ

    Dr Benjamin Mullish

  300. Global patterns of cardia and non-cardia gastric cancer incidence in 2012

    Article • Gut, March 2015, BMJ

    Dr Benjamin Mullish

  301. Case 25-2014: A Man with Ulcerative Colitis and Bloody Diarrhea

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2014, New England Journal of Medicine (NEJM/MMS)

    Dr Benjamin Mullish

  302. Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection

    Article • QJM, September 2014, Oxford University Press (OUP)

    Dr Benjamin Mullish

  303. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

    Article • Alimentary Pharmacology & Therapeutics, September 2014, Wiley

    Dr Benjamin Mullish

  304. Low Incidence Of Venous Thromboembolism In Mobile Populations

    Article • Value in Health, May 2014, Elsevier

    Dr Benjamin Mullish

  305. Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature

    Article • BMC Gastroenterology, April 2014, Springer Science + Business Media

    Dr Benjamin Mullish

  306. P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Benjamin Mullish

  307. MRCP Part 1: 400 BOFs

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  308. Cardiology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  309. Clinical pharmacology, therapeutics and toxicology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  310. Clinical sciences

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  311. Dermatology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  312. Endocrinology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  313. Gastroenterology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  314. Haematology and oncology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  315. Neurology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  316. Ophthalmology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  317. Psychiatry

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  318. Renal medicine

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  319. Respiratory medicine

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  320. Rheumatology

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  321. Tropical, infectious and sexually transmitted diseases

    Article • January 2013, Jaypee Brothers Medical Publishing

    Dr Benjamin Mullish

  322. Shoulder pain and dysphagia with an unexpected cause

    Article • BMJ Case Reports, February 2011, BMJ

    Dr Benjamin Mullish

  323. Ascites

    Article • BMJ, February 2010, BMJ

    Dr Benjamin Mullish